Table 1.
Patient and Disease Baseline Characteristics – Inclusion Population (N= 92)
| Total (n=92) | |
|---|---|
| Malea, n (%) | 73 (80.2) |
| Age, years | |
| Median (range) | 59 (34–81) |
| Body mass index ≥ 25 kg/m2, n (%) | 33 (35.9) |
| ECOG Performance status ≤ 2a, n (%) | 90 (100) |
| Dysphagia, n (%) | |
| Grade 0 | 3 (3.3) |
| Grade 1 | 19 (20.7) |
| Grade 2 | 56 (60.9) |
| Grade 3 | 6 (6.5) |
| Grade 4 | 8 (8.7) |
| Time from cancer diagnosisa, months | |
| Median (range) | 3.73 (1.8–14.6) |
| Disease stage (TNM classification)a, n (%) | |
| Stage I | 7 (7.8) |
| Stage II | 8 (8.9) |
| Stage III | 18 (20.0) |
| Stage IV A | 43 (47.8) |
| Stage IV B | 6 (6.7) |
| Stage IV C | 2 (2.2) |
| Other (unknown T, N or M) | 6 (6.7) |
| H&N cancer location, n (%) | |
| Oral cavity | 22 (23.9) |
| Oropharynx | 36 (39.1) |
| Hypopharynx | 15 (16.3) |
| Larynx | 13 (14.1) |
| Nasopharynx | 1 (1.1) |
| Oral cavity and oropharynx | 1 (1.1) |
| Hypopharynx and oropharynx | 3 (3.3) |
| Nasopharynx and oropharynx | 1 (1.1) |
| H&N cancer treatment, n (%) | |
| Radiotherapy | 92 (100.0) |
| Chemotherapy | 61 (66.3) |
| Surgery | 27 (29.3) |
| Targeted therapy | 15 (16.3) |
Notes: aMissing data: sex (1); ECOG performance status (2); Time to diagnosis at enrollment (2); Disease stage (2).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; H&N, head and neck; TNM, tumor, node, metastasis.